Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal triamcinolone timing with Visudyne PDT in neovascular AMD
2006-003261-14Phase 3Completed
- Sponsor
- Retinaklinikken Omnia
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of verteporfin and triamcinolone acetonide in age-related macular degeneration (AMD) and Subretinal neovascularization (2 arms), sponsored by Retinaklinikken Omnia. Primary endpoint: Best-corrected visual acuity (ETDRS). Started Jul 2006; status: completed.
02
Drugs
verteporfintriamcinolone acetonide
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2006-003261-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003261-14.